1. Cost-Effectiveness Analysis of Atorvastatin versus Rosuvastatin in Primary and Secondary Cardiovascular Prevention Populations in Brazil and Columbia 
Joaquín F. Mould-Quevedo, PhD, Magda Vianey Gutiérrez-Ardila, DMD, MSc(c), Jaime Eduardo Ordóñez Molina, MD, PhD, Brett Pinsky, MPH, Nicolás Vargas Zea, MBA, MSc 
Value in Health Regional Issues 
Volume 5, Pages (December 2014)
DOI: /j.vhri
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1
 (A) Treatment decision tree, primary prevention, and (B) Markov health states, primary prevention and secondary prevention models. CV, cardiovascular; CVD, cardiovascular disease.
Value in Health Regional Issues 2014 5, 48-57DOI: ( /j.vhri )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3. Fig. 2
Discounted total cohort (n = 100) costs for (A) primary and (B) secondary prevention. CVD, cardiovascular disease.
Value in Health Regional Issues 2014 5, 48-57DOI: ( /j.vhri )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

4. Fig. 3
Tornado diagrams, primary prevention, for (A) Colombia A20 versus R10 and (B) Brazil A20 versus R10. A20, atorvastatin 20 mg; CVD, cardiovascular disease; LDL, low-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; QALY, quality-adjusted life-year; R10, rosuvastatin 10 mg.
Value in Health Regional Issues 2014 5, 48-57DOI: ( /j.vhri )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

5. Fig. 4
CE acceptability curves, primary prevention, for (A) Colombia A20 versus R10 and (B) Brazil A20 versus R10. A20, atorvastatin 20 mg; CE, cost-effectiveness; QALY, quality-adjusted life-year; R10, rosuvastatin 10 mg.
Value in Health Regional Issues 2014 5, 48-57DOI: ( /j.vhri )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions